Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (727)	2/16/1998 8:39:00 AM
From: BD	Read Replies (1) \| Respond to of 887

Dr. Castro, Can you reply to Jasman's post regarding 5% mortality? From the phase III data I see no fatality's with Depocyt, can you confirm this? Thanks

To: Dr. John M. de Castro who wrote (727)	2/17/1998 12:22:00 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 887

John, What is your take on the arachnoiditis side effects? It seemed to me that, along with the two different ways of viewing DEPO's clinical results, was the big surprise at the Dec ODAC meeting. My thought was that this negative side effect was an important consideration for ODAC in not simply accepting equivalency with methotrexate. I'm wondering if that is likely to be a serious enough concern that it will stand in the way of an FDA approval or that it might at least require further clinicals. Do you know if the Phase IV trials have been set up to treat this side effect differently so that DEPO could demonstrate an effective way of mitigating it? Thanks, Baird